Outset Medical to Report Fourth Quarter 2025 Financial Results on Wednesday, February 11, 2026
Rhea-AI Summary
Outset Medical (Nasdaq: OM) will report fourth quarter and full-year 2025 financial results after market close on Wednesday, February 11, 2026. A conference call with Leslie Trigg, Chair and CEO, and Renee Gaeta, CFO, will be held the same day at 1:30 p.m. PT / 4:30 p.m. ET to discuss financial and operating results. Interested participants must register online to receive dial-in numbers and a unique PIN, and are encouraged to register at least 15 minutes before the call. A live and archived webcast will be available in the Investors section of the company's website.
Positive
- None.
Negative
- None.
News Market Reaction – OM
In the Jan 27 session, OM gained 14.29%, reflecting a significant positive market reaction. Argus tracked a peak move of +13.2% during that session. Our momentum scanner triggered 15 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jan 12 | Q4 and 2025 results | Positive | +22.1% | Unaudited Q4 and full-year revenue growth with lower cash burn. |
| Jan 05 | Investor conference | Neutral | +2.7% | J.P. Morgan Healthcare Conference presentation and webcast access for investors. |
| Nov 10 | Q3 2025 earnings | Neutral | +0.1% | Modest revenue growth, margin improvement, but reduced full-year revenue guidance. |
| Nov 05 | Clinical outcomes data | Positive | -6.0% | Strong Tablo-based insourced dialysis outcomes and efficiency metrics from research. |
| Nov 05 | Conference appearance | Neutral | -1.6% | Stifel Healthcare Conference presentation with live and archived webcast. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
News tied to financial performance or major investors has often aligned with positive price moves, while strong research data once saw a negative reaction, showing occasional divergence between fundamentals and trading.
Recent news for OM has centered on financial results and investor outreach. On Jan 12, 2026, unaudited Q4 and 2025 results with $28.9M Q4 and $119.5M full-year revenue led to a 22.15% gain. Earlier, a Schedule 13G on Jan 14, 2026 showed a 9.4% passive stake. Q3 2025 results on Nov 10 combined modest growth with lowered guidance and barely moved the stock. Clinical research data on Nov 5, 2025 coincided with a -5.97% move, contrasting with otherwise generally aligned reactions.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN JOSE, Calif., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that it will release financial results for the fourth quarter and full-year 2025 after the close of trading on Wednesday, February 11, 2026.
On the same day, at 1:30 p.m. Pacific time (4:30 p.m. Eastern time), Leslie Trigg, Chair and Chief Executive Officer, and Renee Gaeta, Chief Financial Officer, will host a conference call to discuss financial and operating results.
Conference Call Details
The conference call will begin at 1:30 p.m. Pacific time (4:30 p.m. Eastern time) on Wednesday, February 11, 2026. Those interested in joining the conference call may do so by registering online. Once registered, participants will receive dial-in numbers and a unique pin to join the call. Participants are encouraged to register more than 15 minutes before the start of the call. A live and archived webcast of the event will be available on the “Investors” section of the Outset website at https://investors.outsetmedical.com/.
About Outset Medical, Inc.
Outset is a medical technology company transforming the dialysis experience across the continuum of care with a first-of-its-kind technology. The Tablo® Hemodialysis System, FDA-cleared for use from hospital to home, is trusted by more than 1,000 U.S. healthcare facilities and has enabled millions of treatments delivered by thousands of nurses. Designed to reduce the cost and complexity of dialysis, Tablo combines water purification and on-demand dialysate production into a single, integrated system that connects seamlessly with Electronic Medical Record systems and a proprietary data analytics platform. This enterprise solution empowers providers to develop an in-house dialysis program where they are in control – enabling better operational, clinical, and financial outcomes. Outset is redefining what’s possible in kidney care through innovation, scale, and a relentless commitment to improving the lives of patients and the professionals who care for them. For more information, visit www.outsetmedical.com.
Contact
Jim Mazzola
jmazzola@outsetmedical.com
